Alpha 1 MZ World Wide

According to a report, (excerpt below) there are more than 35 Million Alpha 1 MZ's in the world. Because the "Z" DNA error originated from the Vikings in Scandinavia, you see the highest prevalence in Europe and parts of the world due to migration of Europeans.
Although it is not possible to give an accurate number, this report provides a very good insight.  
 

The result of the study reveals an impressive number of MZs of more than 35 million in 74 countries of the world with available data. Seventy-five percent of them are people of Caucasian European heritage, mostly living in Europe, America, Australia and New Zealand. Twenty percent of the remaining MZs live in Asia, with the highest concentrations in the Middle East, Eastern¸ Southern, and South-eastern regions of the Asian continent. The
remaining five percent are Africans residing in Western and Eastern Africa.

Previous studies have found that among patients diagnosed with COPD the prevalence of the PiMZ genotype ranges from 1% to 22%.  According to these percentages of genetic penetrance, up to one-fifth of the estimated 35 million of the MZ carriers from the 74 selected countries (ie, approximately 7 million) will develop COPD.

​

The conclusion of this study is:
There are an impressive number of MZ carriers (between 2% and 4% of the population of European heritage), living in Europe; America, Australia and New Zealand countries, and a smaller but not negligible number in other African, Asian and Central and South American countries, where apart from smoking, indoor, outdoor and industrial pollution can play an important role in the development of COPD.
The biological mechanisms that underlie increased risk among MZs are only partially known, and therefore more studies are needed to know what the contribution of the genetic defect and of the exogenous factors is, together and lately, in the development of COPD in MZ carriers to know the exact risk that this genotype carries.